Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

August 31, 2012

Study Completion Date

May 31, 2013

Conditions
Leishmaniasis
Interventions
BIOLOGICAL

LEISH-F3 + GLA-SE

20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.

BIOLOGICAL

LEISH-F3 + GLA-SE

20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.

BIOLOGICAL

LEISH-F3 alone

20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.

Trial Locations (1)

98418

Comprehensive Clinical Development NW, Inc., Tacoma

All Listed Sponsors
lead

Access to Advanced Health Institute (AAHI)

OTHER

NCT01484548 - Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter